Spiriva 2019 U.S. PROMOTIONAL AUDIT REPORT

Spiriva 2019 U.S. PROMOTIONAL AUDIT REPORT

  • July 2020 •
  • 26 pages •
  • Report ID: 5210639 •
  • Format: PDF
The 5 Key Questions Addressed by this Report:
• How many physicians were reached by Spiriva through reportable promotional activity in 2019 and how does this compare to its peer set in the Asthma and Chronic Obstructive Pulmonary Disease markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Boehringer Ingelheim’s depth of coverage vary within key specialties (e.g., Family Medicine, Internal Medicine, Pulmonology, Allergy/Immunology, and Critical Care Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Spiriva throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Spiriva in 2019?

Data Sources and Methodology:
• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 55,100 paid interactions across 20,400 physicians made on behalf of Spiriva were carefully examined to support our analysis. In addition, interaction data from 24 peer products (e.g. Alvesco, Anoro, Asmanex, Bevespi, Breo, Brovana, Cinqair, Combivent, Daliresp, Duaklir Pressair, Dulera, Dupixent, Fasenra, Lonhala Magnair, Nucala, Perforomist, Qvar, Stiolto, Symbicort, Trelegy Ellipta, Tudorza, Wixela Inhub, Xolair, and Yupelri ) was leveraged to provide benchmarking and market insights.